Home
About
Overview
Sharing Data
ORCID
Help
History (1)
The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow.
The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow. Neoplasia. 2011 Nov; 13(11):1058-68.
View in:
PubMed
subject areas
Amino Acid Substitution
Amino Acid Substitution
Animals
Animals
Antineoplastic Agents
Antineoplastic Agents
Bone Marrow Cells
Bone Marrow Cells
Bone Marrow Neoplasms
Bone Marrow Neoplasms
Cell Transformation, Neoplastic
Cell Transformation, Neoplastic
Cells, Cultured
Cells, Cultured
Drug Evaluation, Preclinical
Drug Evaluation, Preclinical
Janus Kinase 2
Janus Kinase 2
Male
Male
Mice
Mice
Mice, Inbred C57BL
Mice, Inbred C57BL
Mice, Transgenic
Mice, Transgenic
Myeloproliferative Disorders
Myeloproliferative Disorders
Phenylalanine
Phenylalanine
Protein Kinase Inhibitors
Protein Kinase Inhibitors
Stilbenes
Stilbenes
Valine
Valine
authors with profiles
Zhizhuang J Zhao